In light of the more than 1,500 clinical trials, 420 companies, 190 universities, labs, and R&D hubs, 95 treatment candidates, and 85 vaccine candidates now working to neutralize the COVID-19 pandemic and promote beneficial outcomes, Deep Knowledge Analytics has released its Covid-19 MedTech Analytics IT-Platform, which maps the science, technology, and medicine activities in the global COVID-19 landscape.
The platform is designed to serve as a comprehensive database of the most relevant entities, technologies, and developments, the company reports. The dashboard provides an overview of entities at the forefront of neutralizing the pandemic; the objective is to cover all major sectors and relevant activities in the community including R&D, treatment, diagnostic and vaccine development, and practical applications occurring globally.
The platform is intended as a distributed knowledge base, crowdsourcing additional data from relevant experts. Deep Knowledge Group has aggregated data from multiple sources and qualified experts within its existing network, and welcomes additional contributions from those interested in expanding the scope and reach of the platform. The group plans to unveil enhanced features including extensive filter and search functions which will allow decision makers to use the platform to derive insights to optimize outcomes in the wake of the pandemic.
Individuals may submit new entries for review here. Authorized representatives of entities, organizations, and individuals featured on the platform may claim ownership of the profiles by selecting edit profile and clicking claim ownership. Claiming ownership enables authorized people to edit and update personal profiles and company information.
To access the interactive dashboard, visit Covid-19 MedTech Analytics IT-Platform.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.